Overview: HBV Drug Resistance Genotyping TestIntroduction: The HBV Drug Resistance Genotyping Test identifies hepatitis B drug resistance mutations to guide treatment, preventing liver damage. Following 2023 AASLD guidelines, it uses PCR for high specificity, aiding in infectious disease screening. This test is critical for guiding antiviral therapy adjustments, optimizing treatment, and improving outcomes in virology for patients with chronic hepatitis B.
Other Names: HBV Resistance Assay, Hepatitis B Genotyping Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: HBV resistance testing began in the 2000s with antiviral resistance research. PCR-based genotyping improved in the 2010s, enhancing mutation detection.
Purpose: Identifies HBV drug resistance mutations, guides antiviral therapy, and monitors resistance in patients to prevent liver damage.
Test Parameters: 1. HBV Drug Resistance Mutations
Pretest Condition: No fasting required. Collect whole blood, plasma, serum, or saliva at any time. Report treatment history, symptoms like fatigue, and list medications.
Specimen: 2-5 mL whole blood (EDTA), 2-4 mL plasma (EDTA), 2-5 mL serum (SST), or 1-2 mL saliva (sterile container). Centrifuge within 1 hour. Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, liver pain, or history of chronic hepatitis B. Include current medications, especially antivirals, and treatment response history.
Consent: Written consent required, detailing the tests purpose, resistance implications, and potential need for treatment adjustments.
Procedural Considerations: Uses PCR to identify HBV drug resistance mutations (e.g., lamivudine resistance). Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Poor DNA quality, low viral load, or contamination can affect results. Antiviral therapy may suppress detectable mutations.
Clinical Significance: Identified resistance mutations (e.g., YMDD) guide antiviral therapy changes. Negative results may indicate effective treatment or low viral load.
Specialist Consultation: Consult a hepatologist for result interpretation and antiviral therapy planning.
Additional Supporting Tests: HBV DNA, HBsAg, or liver function tests to assess treatment response and disease status.
Test Limitations: Low viral loads may limit mutation detection. Clinical correlation and serial testing are needed.
References: AASLD Hepatitis B Guidelines, 2023; Hepatology, Lok AS, 2022.
